Business EconomyPosted at: Oct 21 2026 11:26AM


Dr. Reddy’s gets DCGI approval for Zytorvi in Advanced Oesophageal Cancer

Hyderabad, Oct 21 (UNI) Dr. Reddy’s Laboratories has received approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab), in combination with cisplatin and paclitaxel, for the first-line treatment of adults with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (ESCC).
The approval marks the drug’s second approved indication in India, following its earlier approval for nasopharyngeal carcinoma, the Hyderabad based pharma giant said in a press release on Wednesday.
The approved treatment does not require patient selection based on PD-L1 expression, allowing eligible patients to be considered for therapy regardless of their biomarker status.
The approval is supported by findings from the Phase III JUPITER-06 clinical trial, in which toripalimab combined with chemotherapy reduced the risk of disease progression or death by 42 per cent compared with chemotherapy alone.
At the final overall survival analysis, median overall survival was 17.7 months for patients receiving toripalimab with chemotherapy, compared with 12.9 months for those receiving chemotherapy alone.
M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said the approval would extend access to immunotherapy for patients with advanced oesophageal squamous cell carcinoma and provide physicians with an additional first-line treatment option.
The company entered into a licensing and commercialisation agreement with Shanghai Junshi Biosciences in 2023, securing exclusive rights to develop and commercialise toripalimab in 21 countries, including India.
Oesophageal cancer was the fourth leading cause of cancer-related deaths in India in 2024, accounting for approximately 8.1 per cent of all cancer deaths. Oesophageal squamous cell carcinoma accounts for around 80 per cent of oesophageal cancer cases in the country, the press added.
UNI KNR ARN
Please log in to get detailed story.
Tags: #Dr. Reddy’s gets DCGI approval for Zytorvi in Advanced Oesophageal Cancer
More News

Embrace AI as an opportunity, don't fear job losses: Ex-IT Minister KTR tells youth

24 Oct 2026 | 10:22 PM

Hyderabad, Oct 24 (UNI) Former IT Minister and Bharat Rashtra Samithi (BRS) working President K.T. Rama Rao (KTR) on Saturday called upon the youth to embrace Artificial Intelligence (AI) as a powerful frontier for innovation and employment rather than viewing it as a threat to livelihoods, underscoring the critical need for continuous upskilling.

see more..

Godrej properties plans launches worth Rs 32,000 crore despite drop in profit

24 Oct 2026 | 9:36 PM

Mumbai, Oct 24 (UNI) Mumbai-headquartered real estate developer Godrej Properties officially announced that it has lined up project launches worth more than Rs 32,000 crore for the second half of FY27, even as its consolidated net profit fell 62 per cent year on year in the September quarter (Q3).

see more..

Telangana unveils AI avatar of IT Minister at DevFest 2026

24 Oct 2026 | 8:02 PM

Hyderabad, Oct 24 (UNI) Telangana's technology push received a boost with the unveiling of an artificial intelligence (AI) avatar of IT Minister D Sridhar Babu at DevFest 2026 here on Saturday, as more than 3,000 developers, students and technology professionals gathered for the annual conference.

see more..

PFRDA bets on mutual fund distributors, digital rails to scale up NPS

24 Oct 2026 | 7:33 PM

Bengaluru, Oct 24 (UNI) The Pension Fund Regulatory and Development Authority (PFRDA) is turning to mutual fund distributors and digital platforms to address a fundamental challenge confronting the National Pension System (NPS) — how to expand its reach when the low cost of the product leaves limited room for conventional distribution economics.

see more..

Kotak Mahindra Bank Q2 PAT rises 29 pc to Rs 4,212 crore; NIM falls to 4 31 pc

24 Oct 2026 | 6:25 PM

Mumbai, Oct 24 (UNI) Kotak Mahindra Bank on Saturday reported a 29 per cent year-on-year increase in standalone net profit to Rs 4,212 crore for the second quarter ended September 30, 2026, but its net interest margin (NIM) moderated to 4.31 per cent following the mobilisation of around Rs 55,000 crore in foreign currency non-resident bank (FCNR(B)) deposits.

see more..